ArticleEClinicalMedicine2024

Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.

Masato Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.